title: A case report of primary unilateral adrenal NK/T cell lymphoma: good clinical outcome with trimodality treatment.
abstract: Primary natural killer (NK)/T cell lymphoma of adrenal glands is an extremely rare tumor with aggressive clinical behavior. There have only been a few cases reported worldwide and the highest reported survival was 90 days. We report the first case of primary unilateral adrenal NK/T cell lymphoma in China with good outcome.
  
  
  
  This is a 28-year-old man who presented with abdominal pain and was found to have a large mass on the left adrenal and the top of the renal region. The patient underwent surgical resection and the pathology revealed primary adrenal NK/T cell lymphoma. He received adjuvant sandwich therapy encompassing sequential chemotherapy, radiotherapy and chemotherapy. The patient remains clinically and symptomatically disease-free with over two years follow up.
  
  
  
  Given the rarity of this disease, there is limited experience with regard to its diagnosis and treatment. This case report will add to the scant literature on this tumor and will be useful for the differential diagnosis and treatment of adrenal disease.
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Hu
authors.affiliation: Department of ENT, Wuhan Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430034, China.
authors.forename: Weimin
authors.initials: W
authors.lastname: Xu
authors.affiliation: Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, China.
authors.forename: Mingwei
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Dermatology, Wuhan Medical & Healthcare Center for Women and Children, Wuhan, 430015, China. cecilyhuliu@163.com.
authors.forename: Pan
authors.initials: P
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, China. hg7913@hotmail.com.|Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. hg7913@hotmail.com.
authors.forename: Guang
authors.initials: G
authors.lastname: Han
authors.affiliation: Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
authors.forename: Chi
authors.initials: C
authors.lastname: Lin
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000628:therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods*; D002681:China; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Adrenal glands; Primary natural killer/T cell lymphoma; Trimodality treatment